Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $12.62 Average Target Price from Brokerages

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received an average rating of “Buy” from the eight analysts that are covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $12.6250.

Several research analysts recently commented on CATX shares. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN:CATX opened at $2.87 on Friday. Perspective Therapeutics has a 52 week low of $1.96 and a 52 week high of $6.16. The firm has a fifty day simple moving average of $3.27 and a two-hundred day simple moving average of $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.16 million. On average, equities research analysts predict that Perspective Therapeutics will post -1.1 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commodore Capital LP bought a new stake in Perspective Therapeutics in the first quarter worth $26,424,000. Avidity Partners Management LP raised its stake in shares of Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after acquiring an additional 2,839,266 shares during the period. Vanguard Group Inc. raised its stake in shares of Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares during the period. Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after acquiring an additional 2,864,582 shares during the last quarter. Finally, Spruce Street Capital LP bought a new stake in shares of Perspective Therapeutics in the 1st quarter worth about $10,955,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.